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ANGIOTENSIN SYSTEM POLYMORPHISMS AND TRADI-
TIONAL RISK FACTORS AS PREDICTORS OF HEART FAIL-
URE PROGNOSIS. A. A. Hudson, I. Zineh, PharmD, H. N. Ya-
randi, PhD, T. Y. Langaee, PhD, D. F. Pauly, MD, PhD, J. A.
Johnson, PharmD, University of Florida, Gainesville, FL.
BACKGROUND: Traditional risk factors affect heart failure
(HF) severity and outcomes. We investigated whether angiotensin
system gene polymorphisms would offer additional prognostic infor-
mation when considered with traditional risk factors.
METHODS: Patients with chronic HF were enrolled and fol-
lowed for first event (all-cause mortality, heart transplant, or HF
hospitalization). Logistic regression was used to examine the effects
of covariates on outcome. Variables included risk factors previously
shown to affect prognosis in our population as well as polymorphisms
in the ACE (ACE I/D), angiotensinogen (AGT 235T/C), and angio-
tensin type 1 receptor (AGTR1 1166A/C) genes determined by py-
rosequencing or dHPLC. 	-blocker, ACE inhibitor, and diuretic use
was near unity at baseline and end of follow-up and not included in
the model. Significance for inclusion in the model was set at 0.1.
RESULTS: Patients (n237) were followed for a median of 18
months (6 months min, 36 months max). Significant markers of HF
prognosis are presented (Table).
Variable
Odds
Ratio 90% CI P-value
Serum sodium 0.86 0.78–0.93 0.003
NYHA class 1.84 1.31–2.60 0.003
Previous CABG 1.85 1.03–3.30 0.08
Polymorphisms in three genes of the angiotensin system were not
associated with outcomes, nor were age, race, sex, diabetes, dyslip-
idemia, or serum creatinine.
CONCLUSION: Angiotensin system genes were not associated
with HF prognosis in this population. The high use of ACE inhibitors
and 	-blockers in this population may have ameliorated genetic
influence on prognosis.
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IDENTIFICATION OF GERMLINE GENETIC VARIATIONS
IN THE 5’ REGION OF THE ESTROGEN RECEPTOR BETA
GENE. S. Philips, BS, A. Bermes, BS, A. T. Nguyen, BS, R.
Luzcando, BS, P. B. Narayanan, PhD, D. A. Flockhart, MD, PhD,
T. C. Skaar, PhD, Indiana University, Indianapolis, IN.
BACKGROUND: Tamoxifen therapy causes variable phenotypic
effects on target tissues. Currently, there is no way to predict which
patients will have beneficial or harmful side effects from it. Germline
genetic polymorphisms in the estrogen receptors (ERs) are associated
with altered responses to estrogenic therapies and baseline parameters
(e.g. bone mineral density and serum lipids). Little information is
available on the germline genetic variations in the estrogen receptor
beta (ER	) gene. We hypothesize that genetic variations in the ERs
may account for part of the variability in the tamoxifen induced side
effects. The aim of this study was to identify genetic polymorphisms
in the promoter of the ER	 gene.
METHODS: Using a bioinformatic approach, we compared the
promoter sequences of the human, chimpanzee, rat and mouse ER	
genes. We found a region of strong homology immediately upstream
of the exon 0N. This region has also been shown to be a site of in vivo
methylation. Therefore, we resequenced approximately 1.6 kb of the
ER	 promoter, exon 0N and intron 1 in 50 African-American (AA)
and 50 Caucasian (Cau) subjects.
RESULTS: In AA samples, we found 5 single nucleotide poly-
morphisms (SNPs) in the promoter, one of which altered the pre-
dicted TATA box in the promoter. We also found a SNP in intron 1
that was observed in both Cau and AA. There were no SNPs detected
in the exon 0N.
CONCLUSION: The promoter of the ER	 gene contains at least
one SNP that may alter its transcriptional activity and tamoxifen
responses.
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IDENTIFICATION OF GENETIC POLYMORPHISMS IN 40
CHEMOTHERAPY PATHWAY GENES. R. R. Freimuth, PhD, S.
Marsh, PhD, M. Xiao, PhD, P. Kwok, MD, PhD, H. L. McLeod,
PharmD, Washington University, University of California, San
Francisco, St. Louis, MO.
BACKGROUND: We set out to identify functionally significant
common polymorphisms in 40 genes involved in the pharmacokinetic
or pharmacodynamic pathways of anticancer drugs.
METHODS: We used a pooled approach to resequence 120 DNA
samples from African-Americans, Asians, and Caucasians (40 sam-
ples each).
RESULTS: Approximately 338 kb of sequence was analyzed
from each sample. 193 of the 711 variant loci that were identified
were located in exons. The PolyMAPr program was used to mine the
dbSNP, JSNP, and CGAP databases. 243 of the 711 variants were
novel, and 78% of the remaining 468 were listed as unvalidated in the
databases. Based on estimated allele frequencies, 274 variants were
population-specific and 284 were common to all 3 groups. Of the 115
ORF SNPs, 61 were population-specific and 31 were in all 3 groups.
Resequencing and database mining identified 523 variants in the
ORF. The PolyPhen program was used to predict functional signifi-
cance of 275 nonsynonymous biallelic SNPs: 174, 43, and 48 were
predicted to be benign, possibly damaging, and probably damaging,
respectively. Estimated allele frequency and BLOSUM62 score de-
creased with increasing predicted severity of the amino acid change.
CONCLUSIONS: These results will aid future pharmacogenetic
studies of anticancer drugs.
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TAMOXIFEN THERAPY REDUCED PLATELET COUNTS
WITHOUT CHANGE IN PLATELET FUNCTION. Y. Jin, MD, B.
Ward, A. Storniolo, MD, Z. Desta, PhD, A. Nguyen, D. Hayes, MD,
V. Stearns, MD, D. A. Flockhart, MD, PhD, Indiana University,
University of Michigan, Indianapolis, IN.
BACKGROUND/AIMS: Tamoxifen therapy can cause a 4%
decrease in platelet count, yet increases risk of thrombosis. We
hypothesized that this decrease was influenced by concentrations of
tamoxifen or its metabolites that may lead to changes in platelet
function.
METHODS: Candidates for tamoxifen therapy (n88) partici-
pated in a prospective, observational trial. Before and 4 months after
tamoxifen treatment, we measured platelet counts (N88), platelet
aggregation (N17), and plasma concentrations of tamoxifen and its
metabolites (N41).
RESULTS: Tamoxifen therapy led to a 4% decrease in platelet
counts (P 0.039) in our cohort. This decrease was negatively
correlated with plasma concentrations of endoxifen (R2 0.27,
P0.0006) and 4-hydroxy tamoxifen (R2 0.22, P0.003), but not
with tamoxifen and N-desmethyl tamoxifen.. There were no signifi-
cant changes in either ADP (13.3312.3  vs 11.611.5 , P 
0.12) or arachadonic acid (9.646.1 vs 7.037.6 , P0.19) in-
duced platelet aggregation.
CONCLUSION: Decrease in platelet counts after tamoxifen was
negatively correlated with endoxifen and 4-hydroxy tamoxifen con-
centrations, and did not lead to changes in platelet function.
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